Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The participants of this study were rheumatoid arthritis (RA) patients for whom adalimumab was prescribed. They must have met the following conditions:~* Disease duration of RA ≤2 years~* Methotrexate (MTX) administration ≥3 months prior to starting adalimumab~* Dose of MTX ≥12mg/week~* Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) score \>3.2~Exclusion Criteria:~* Participants who had been previously treated with biologics (including tumor necrosis factor \[TNF\] inhibitors and others)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants treated with adalimumab (Type: None): 40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).